Rype addresses the dilemma of choosing between expensive or low-quality office furniture that contributes to carbon emissions and waste. By remanufacturing high-quality used office furniture, Rype offers cost-effective solutions with 80% lower carbon emissions and waste, while creating local jobs. Their mission is to significantly reduce office carbon emissions and costs through sustainable, circular economy practices, including exclusive furniture ranges made from waste materials. Rype's comprehensive services encompass furniture sourcing, remanufacturing, and employing marginalized individuals, contributing to a more environmentally friendly and socially responsible approach to office furnishings.
days to go:
Extended
investment:
Withheld
GoPower offers comprehensive portable solar energy solutions, designed to save you money and reduce your environmental impact. Their user-friendly solar panels eliminate the need for complex installations, allowing easy setup anywhere. Their portable solar power stations, providing up to 1000w/1280WH at 240v, are perfect for various applications such as home offices, garden rooms, boats, events, and more. With multiple output sockets and versatile charging options including solar panels and mains electricity, GoPower provides a greener and cost-effective energy alternative.
days to go:
Extended
investment:
£10,000
TeaTime deliver fresh and healthy tea blends straight to your door. Simply choose how often you wish to receive your box, weekly or fortnightly and TeaTime will dispatch a selection of 4 of their blends out to you within 48 hours.
days to go:
Expired
investment:
£18,940
Roqberry is a high-quality blended speciality tea made for millennial foodies. The company has received 20 Great Taste Awards and has secured listings with high-end distributors. It is stocked in speciality restaurants and retailers. Roqberry has been named as one of The Independent's "Best Plastic-Free Teabags". Already selling its products via its online shop and Amazon, the company is in discussion with other F&B chains, retailers and a major hotel. Roqberry is looking forward to scaling its B2B sales and B2C by hiring an account manager and new ops.
days to go:
Expired
investment:
£152,290
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.
days to go:
Expired
investment:
£270,543
Winebuyers connect vineyards and wine merchants directly to the end consumer revolutionising a traditional industry. They make their revenue by charging the suppliers a monthly fee and have had 2,700 companies registering their interest to be involved in the platform. The funding will go towards strengthening their infrastructure, extending their marketing activities and to growing the business quickly and efficiently.
(SEIS Partial)
days to go:
Expired
investment:
£568,870
Peckwater Brands (PB) is a company engaged in the growing cloud kitchen/delivery business that runs virtual restaurant brands from the kitchens of existing restaurants. It argues that restaurants need to pay high street rents and staff wages no matter how many diners visit. Nearly 5,000 restaurants have closed in the UK since 2015 due to not being able to fulfil these tasks. PB aims to change this scenario. It helps restaurant partners use their existing staff and kitchen capacity better, and help keep struggling businesses running. The company received more than 10,000 customer orders through Deliveroo and Uber Eats. It witnessed more than £250,000 in customer sales since June 2020 and is spread across London, Manchester, Leeds, and Coventry. PB has launched four brands with four more in the pipeline. It will use the investment to get more partners, launch more brands, and acquire more customers.
days to go:
Expired
investment:
£232,208
Cranes develop acoholic, cranberry flavoured drinks. Currently their product range consists of 3 different variations of cranberry cider and also a cranberry liqueur. Current stockists include the online supermarket Ocado, as well as many other local shops and bars.
days to go:
Expired
investment:
£194,634
Established by a team from a Michelin star restaurant, The Gaff is a small plate restaurant offering food in contemporary, comfortable, and relaxed surroundings. The first restaurant was opened in May 2019 and aspires for a Michelin Accreditation. The concept of small plate menus was the fourth biggest restaurant concept trend of 2019 which Gaff wants to capture. Gaff has been reviewed in The Good Food Guide 2020 and mentions by prominent food bloggers such as Kavita Favelle. They have also received good customer ratings with over 87% 5-star rating on Res Diary and a 75% rating on TripAdvisor. The funds raised will be utilised to open a second restaurant in Bath and three more around the UK.
days to go:
Expired
investment:
£71,950
Inspira Pharmaceuticals (IP) is forming a possible new therapy for COVID-19. IP asserts that its in-lab plant-based molecular formulation has killed over 95% of the SARS-CoV-2 virus. The company aims to understand whether a COVID-19 patient can safely inhale the formulation directly into their lungs as an effective treatment. IP has secured cornerstone investment from biotech angel investors and a Singaporean Venture Capitalist (VC) for its formula. IP argues that its technology has the potential for addressing other respiratory infections such as cystic fibrosis, influenza and the common cold in the coming months. The company will use the investment to develop an effective new drug, which will include further laboratory analysis, safety testing, and preparation for human trials.
days to go:
Expired
investment:
£357,179
